Moleculin Biotech (MBRX) Competitors $0.39 +0.05 (+14.35%) Closing price 04:00 PM EasternExtended Trading$0.41 +0.02 (+6.22%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, PMN, and GOVXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Lipocine Cingulate Mannatech Gelteq Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs Lipocine (NASDAQ:LPCN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends. Is LPCN or MBRX more profitable? Lipocine's return on equity of -26.68% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -26.68% -24.77% Moleculin Biotech N/A -278.80%-100.11% Which has preferable earnings & valuation, LPCN or MBRX? Lipocine has higher revenue and earnings than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$11.20M1.49$10K-$1.02-3.05Moleculin BiotechN/AN/A-$21.76MN/AN/A Which has more volatility and risk, LPCN or MBRX? Lipocine has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Do analysts recommend LPCN or MBRX? Lipocine currently has a consensus target price of $9.00, suggesting a potential upside of 189.39%. Moleculin Biotech has a consensus target price of $4.00, suggesting a potential upside of 928.81%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer LPCN or MBRX? In the previous week, Lipocine and Lipocine both had 1 articles in the media. Moleculin Biotech's average media sentiment score of 1.11 beat Lipocine's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in LPCN or MBRX? 9.1% of Lipocine shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 1.9% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryLipocine beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.49M$2.86B$5.45B$8.93BDividend YieldN/A2.44%5.22%4.01%P/E RatioN/A20.4427.2420.06Price / SalesN/A283.79426.37117.54Price / CashN/A41.7026.2128.59Price / Book0.227.397.925.56Net Income-$21.76M-$55.04M$3.17B$248.56M7 Day Performance28.78%3.43%4.40%7.56%1 Month Performance-41.97%0.16%2.64%8.54%1 Year Performance-88.86%4.49%35.04%21.81% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech3.1483 of 5 stars$0.39+14.4%$4.00+928.8%-90.0%$5.49MN/A0.0020Positive NewsHigh Trading VolumeLPCNLipocine1.5717 of 5 stars$3.16-4.0%$9.00+184.8%-55.1%$17.60M$11.20M-3.1010CINGCingulate2.7003 of 5 stars$4.07+0.5%$26.00+538.8%+1,174.1%$17.19MN/A-0.4820Gap UpMTEXMannatech0.2741 of 5 stars$9.35+3.9%N/A+25.8%$17.11M$117.87M-93.50250High Trading VolumeGELSGelteqN/A$1.73-4.4%N/AN/A$17.08M$100K0.00N/AGap DownCARMCarisma Therapeutics2.3672 of 5 stars$0.39-2.2%$1.93+391.6%-64.7%$16.74M$19.63M-0.2520MRKRMarker Therapeutics3.2093 of 5 stars$1.53+4.8%$13.17+760.6%-68.3%$16.52M$6.59M-1.1560Positive NewsGap UpCTXRCitius Pharmaceuticals2.3996 of 5 stars$1.59+3.9%$53.00+3,233.3%-83.4%$16.27MN/A0.0020High Trading VolumeRVPHReviva Pharmaceuticals2.2537 of 5 stars$0.38+12.9%$9.00+2,261.6%-68.5%$16.20MN/A-0.485Gap UpHigh Trading VolumePMNPromis Neurosciences3.3859 of 5 stars$0.48+0.7%$4.50+830.1%-74.1%$15.70MN/A-9.685Gap UpGOVXGeoVax Labs3.3284 of 5 stars$0.87-9.8%$11.10+1,182.2%-82.9%$15.29M$3.95M-0.2410Analyst Downgrade Related Companies and Tools Related Companies LPCN Competitors CING Competitors MTEX Competitors GELS Competitors CARM Competitors MRKR Competitors CTXR Competitors RVPH Competitors PMN Competitors GOVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBRX Stock Alerts